In-depth understanding of molecular characteristics of gastric cancer enabled us to realize personalized medicine with targeted agents in gastric cancer treatment.

The investigators initiated open-label, randomized, controlled phase II, multi-arm trial comparing targeted therapy based on tumor molecular profiling with standard paclitaxel therapy as second line treatment.

In-depth understanding of molecular characteristics of gastric cancer enabled us to realize personalized medicine with targeted agents in gastric cancer treatment.The investigators initiated open-label, randomized, controlled phase II, multi-arm trial comparing targeted therapy based on tumor molecular profiling with standard paclitaxel therapy as second line treatment.

Inclusion Criteria:

1. Histologically or cytologically confirmed locally advanced or metastatic gastric cancer and gastroesophageal junction cancer

2. Eastern Cooperative Oncology Group performance status of 0 to 1

3. Male or female; ≥ 19 years of age

4. On or progression after 1st line palliative chemotherapy

5. Subjects with evaluable lesion (using RECIST 1.1 criteria)

6. Subjects who meet the following criteria:

   • Absolute neutrophil count ≥ 1000 /µL
   • Platelet count ≥ 75,000/ µL
   • Serum creatinine < 1.5 x upper limit of normal or Creatinine clearance ≥60 mL/min
   • aspartate aminotransferase and alanine transaminase 3 x upper limit of normal

Exclusion Criteria:

• Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study